The intestinal microbiota is instrumental to shape our immune system and its functions. At Recolony, we aim to harness the potential of beneficial gut microbiota and to develop a new class of cancer immunotherapy. In that effort, we identified specific bacterial species that are less abundant in CRC patients compared to healthy individuals. Oral supplementation of these bacteria causes a very effective anti-tumor activity in various cancer models through specific activation of cytotoxic T-cells.